风中残烛
风前残烛
元．左克明《古乐府．怨歌行》
【原文】
天德悠且长，人命一何促。
百年未几时，奄若风吹烛。
嘉宾难再遇，人命不可续。
齐度游四方，各系太山录。
人间乐未央，突然归东岳。
当须荡中情，游心恣所欲。
【赏析】
“风中残烛”刘因引用元．左克明《古乐府．怨歌行》中“百年未几时，奄若风吹烛”之句。
刘因，字梦骥，元时初年，睿城（今河北省容城县）人。
他非常聪敏，并且肯下工夫读书，著有《静修集》和《四书集义精要》等。
刘因幼小丧父，一向对母亲很孝顺，成人以后，曾在朝廷任右赞善大夫，他在朝中做官，清正廉洁，经常利用空闲时间回到家中照顾已经年迈的母亲。
后来因为母亲生病，身边无人照料，看到母亲躺在床上那副满脸皱纹，容颜枯槁的样子，刘因心酸得潸然泪下，为自己不能时刻守候在母亲床前而愧疚，就上书当朝皇帝，说母亲生病需要人照顾，然后就辞去官职，回家一心一意地侍奉母亲。
不久，朝廷又叫刘因去做官，他却不愿意再去，有人问他为什么放弃做官的大好机会，他回答说：“古乐府《怨歌行》中有‘百年未几时，奄若风中烛’之句。我母亲现在已经90岁了，也好比是‘风中残烛’ 大风中一支快燃尽的蜡烛，在世不久了，我怎么可以扔下她不管离她远去，而自己贪图那富贵荣华呢？”
“风中残烛”，“ 风前残烛”like the candle before the wind像在风中烧残，一支随时都会熄灭，即将燃尽的蜡烛。like the candle flicking in the wind，
人们用来形容老年人精力衰竭，old and ailing在世不久。short time left for aged people.
“风烛残年”人像在风中烧残的蜡烛，容易熄灭，形容年老病弱，the declining ages is like a candle in the wind，朝不保夕in imminent danger of death. https://t.cn/z82Gb98
风前残烛
元．左克明《古乐府．怨歌行》
【原文】
天德悠且长，人命一何促。
百年未几时，奄若风吹烛。
嘉宾难再遇，人命不可续。
齐度游四方，各系太山录。
人间乐未央，突然归东岳。
当须荡中情，游心恣所欲。
【赏析】
“风中残烛”刘因引用元．左克明《古乐府．怨歌行》中“百年未几时，奄若风吹烛”之句。
刘因，字梦骥，元时初年，睿城（今河北省容城县）人。
他非常聪敏，并且肯下工夫读书，著有《静修集》和《四书集义精要》等。
刘因幼小丧父，一向对母亲很孝顺，成人以后，曾在朝廷任右赞善大夫，他在朝中做官，清正廉洁，经常利用空闲时间回到家中照顾已经年迈的母亲。
后来因为母亲生病，身边无人照料，看到母亲躺在床上那副满脸皱纹，容颜枯槁的样子，刘因心酸得潸然泪下，为自己不能时刻守候在母亲床前而愧疚，就上书当朝皇帝，说母亲生病需要人照顾，然后就辞去官职，回家一心一意地侍奉母亲。
不久，朝廷又叫刘因去做官，他却不愿意再去，有人问他为什么放弃做官的大好机会，他回答说：“古乐府《怨歌行》中有‘百年未几时，奄若风中烛’之句。我母亲现在已经90岁了，也好比是‘风中残烛’ 大风中一支快燃尽的蜡烛，在世不久了，我怎么可以扔下她不管离她远去，而自己贪图那富贵荣华呢？”
“风中残烛”，“ 风前残烛”like the candle before the wind像在风中烧残，一支随时都会熄灭，即将燃尽的蜡烛。like the candle flicking in the wind，
人们用来形容老年人精力衰竭，old and ailing在世不久。short time left for aged people.
“风烛残年”人像在风中烧残的蜡烛，容易熄灭，形容年老病弱，the declining ages is like a candle in the wind，朝不保夕in imminent danger of death. https://t.cn/z82Gb98
【墨尔本出现疑似病例，病毒检测呈“弱阳性”，卫生厅展开紧急调查】维州卫生当局正在调查一名新冠检测呈“弱阳性”的男子，该男子与墨尔本一家养老机构有关。维州卫生厅今天表示，他们接到了通知，一名从Twin Parks Aged Care Facility养老院去医院就诊的男子，其检测结果呈弱阳性。报道称，该男子此前两次检测呈阴性，但第三次检测呈弱阳性。https://t.cn/A6tt4eit
#新冠疫苗##全球抗疫# 以色列的数据再次肯定辉瑞新冠疫苗有效！
以色列最大的健康管理集团Clalit报告说“与未接种新冠疫苗的相当数量之人群比较，接种了两剂BioNTech?辉瑞新冠疫苗的60万人新冠病毒感染率降低了94%，感染新冠病毒后出现重症的概率下降了92%。”
该集团认为“完成接种第二剂新冠疫苗后的7天起即可产生有效保护，2周或更长时间后保护效果更明显。”
JERUSALEM (Reuters) - Israel's largest healthcare provider on Sunday reported a 94% drop in symptomatic COVID-19 infections among 600,000 people who received two doses of the Pfizer's vaccine in the country's biggest study to date.
Health maintenance organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was also 92% less likely to develop severe illness from the virus.
The comparison was against a group of the same size, with matching medical histories, who had not received the vaccine.
"It shows unequivocally that Pfizer's coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study," said Ran Balicer, Clalit's chief innovation officer.
He added that the data indicates the Pfizer vaccine, which was developed in partnership with Germany's BioNTech, is even more effective two weeks or more after the second shot.
Researchers at the Weizmann Institute of Science, who have been tabulating national data, said on Sunday that a sharp decline in hospitalisation and serious illness identified earlier among the first age group to be vaccinated - aged 60 or older - was seen for the first time in those aged 55 and older.
以色列最大的健康管理集团Clalit报告说“与未接种新冠疫苗的相当数量之人群比较，接种了两剂BioNTech?辉瑞新冠疫苗的60万人新冠病毒感染率降低了94%，感染新冠病毒后出现重症的概率下降了92%。”
该集团认为“完成接种第二剂新冠疫苗后的7天起即可产生有效保护，2周或更长时间后保护效果更明显。”
JERUSALEM (Reuters) - Israel's largest healthcare provider on Sunday reported a 94% drop in symptomatic COVID-19 infections among 600,000 people who received two doses of the Pfizer's vaccine in the country's biggest study to date.
Health maintenance organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was also 92% less likely to develop severe illness from the virus.
The comparison was against a group of the same size, with matching medical histories, who had not received the vaccine.
"It shows unequivocally that Pfizer's coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study," said Ran Balicer, Clalit's chief innovation officer.
He added that the data indicates the Pfizer vaccine, which was developed in partnership with Germany's BioNTech, is even more effective two weeks or more after the second shot.
Researchers at the Weizmann Institute of Science, who have been tabulating national data, said on Sunday that a sharp decline in hospitalisation and serious illness identified earlier among the first age group to be vaccinated - aged 60 or older - was seen for the first time in those aged 55 and older.
✋热门推荐